임상의사결정지원시스템 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 용도별, 제공 형태별, 컴포넌트별, 지역별, 부문 예측(2025-2030년)

Clinical Decision Support Systems Market Growth & Trends:

The global clinical decision support systems market size is anticipated to reach USD 10.71 billion in 2030 and is projected to grow at a CAGR of 11.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Government initiatives aimed at promoting the adoption and integration of Clinical Decision Support Systems (CDSS) are expected to drive market growth by incentivizing hospitals and healthcare organizations to deploy such solutions. For example, in April 2023, the U.S. Department of Health and Human Services (HHS) revised certification program rules to encourage greater utilization of clinical decision support tools. Furthermore, advancements in AI and cloud-based CDSS technologies are projected to accelerate market expansion. The implementation of cloud-based computing to enhance CDSS platforms and database management is also anticipated to positively influence market growth in the forecast period.

During the COVID-19 pandemic, various government and community organizations initiated efforts to bolster the healthcare infrastructure. These initiatives ranged from setting up frontline clinics by state authorities to mobilizing volunteer panels of medical professionals and deploying private telemedicine platforms. Clinical Decision Support Systems (CDSS) proved indispensable during this crisis, assisting physicians in making informed decisions at the point of care.

Consequently, market participants capitalized on this opportunity to address challenges and support frontline healthcare providers. For example, in May 2022, epocrates, a subsidiary of athenahealth, Inc., enhanced its clinical decision support tools to better manage the challenges posed by the COVID-19 pandemic.

Furthermore, several companies are actively implementing strategies to enhance their clinical decision support systems (CDSS) offerings, consolidating their position in the market. For example, in February 2024, Elsevier Health collaborated with OpenEvidence, a prominent provider of AI solutions customized for the medical domain, to launch ClinicalKey AI in the U.S. This collaboration involved integrating advanced medical content with generative artificial intelligence (AI) to assist clinicians in patient-care interactions.

Clinical Decision Support Systems Market Report Highlights:

• Researchers are integrating AI into Clinical Decision Support Systems (CDSS) to process vast data to recommend treatment strategies, highlight potential issues, streamline operations, and support healthcare professionals.
• Standalone CDSS held the largest market share of 30.7% in 2024, because it is widely adopted for its low cost and simplicity. They don't require standardization or extensive clinical expertise and can operate without real patient data.
• Drug allergy alerts accounted for the largest market share of 25.7% in 2024. Several people have allergies to specific drugs, so it is important to have systems that provide allergy alerts
• CDSS services held the largest market share of 42.3% in 2024, as it offers implementation, training, support, customization, and consulting services to help healthcare organizations maximize the value of CDSS software and optimize clinical decision-making
• On-premise segment in delivery mode dominated the market with the largest share of 41.9% in 2024. On-premise CDSS solutions offer flexibility for customization and integration with existing healthcare systems and workflows, catering to specific organizational needs.
• The Clinical Decision Support Systems market in North America accounted for a share of 25.3% of the global revenue in 2024. North American consumers tend to prioritize Clinical Decision Support Systems that reflects current trends, personal style, and individual expression
• North America clinical decision support systems market dominated the global market with over 43.10% revenue share in 2024. This dominance is fueled by the rising demand for IT solutions in healthcare and the emphasis on delivering quality healthcare services

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Product
  • 1.1.2. Application
  • 1.1.3. Delivery Mode
  • 1.1.4. Component
  • 1.1.5. Regional scope
  • 1.1.6. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
  • 1.6.3. Volume price analysis (Model 2)
  • 1.6.4. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. Delivery mode outlook
  • 2.2.4. Component outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Clinical Decision Support Systems Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Adoption of Electronic Health Records (EHRs)
    • 3.2.1.2. Increasing Demand for Quality Care and Patient Safety
    • 3.2.1.3. Advancements in AI and Machine Learning Technologies
    • 3.2.1.4. Supportive Government Initiatives and Healthcare IT Policies
    • 3.2.1.5. Integration of CDSS with Clinical Workflows
    • 3.2.1.6. Need to Reduce Medication Errors and Diagnostic Inaccuracies
    • 3.2.1.7. Emergence of Cloud-Based CDSS Solutions
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Implementation and Integration Costs
    • 3.2.2.2. Data Privacy and Security Concerns
    • 3.2.2.3. Interoperability Challenges with Legacy Systems
• 3.3. Clinical Decision Support Systems Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economical landscape
    • 3.3.2.4. Social landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Clinical Decision Support Systems Market: Product Estimates & Trend Analysis

• 4.1. Product Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Clinical Decision Support Systems Market by Product Outlook
• 4.4. Standalone CDSS
  • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.5. Integrated CPOE with CDSS
  • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.6. Integrated EHR with CDSS
  • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.7. Integrated CDSS with CPOE and HER
  • 4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Clinical Decision Support Systems Market: Application Estimates & Trend Analysis

• 5.1. Application Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Clinical Decision Support Systems Market by Application Outlook
• 5.4. Drug-Drug Interactions
  • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.5. Drug Allergy Alerts
  • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.6. Clinical Reminders
  • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.7. Clinical Guidelines
  • 5.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.8. Drug Dosing Support
  • 5.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Clinical Decision Support Systems Market: Delivery Mode Estimates & Trend Analysis

• 6.1. Delivery Modes Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Clinical Decision Support Systems Market by Delivery Modes Outlook
• 6.4. Web-Based Systems
  • 6.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 6.5. Cloud-Based Systems
  • 6.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 6.6. On-Premise Systems
  • 6.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Clinical Decision Support Systems Market: Component Estimates & Trend Analysis

• 7.1. Component Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Clinical Decision Support Systems Market by Component Outlook
• 7.4. Hardware
  • 7.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 7.5. Software
  • 7.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 7.6. Services
  • 7.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 8. Clinical Decision Support Systems Market: Regional Estimates & Trend Analysis, By Type, By Application, By Delivery Mode, By Component

• 8.1. Regional Market Share Analysis, 2023 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.5. North America
  • 8.5.1. U.S.
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. Canada
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. Mexico
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Europe
  • 8.6.1. UK
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Germany
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. France
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. Italy
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Spain
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Norway
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Sweden
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.8. Denmark
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Japan
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. China
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. India
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Australia
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.5. South Korea
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.6. Singapore
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.2. Mexico
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. Argentina
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.9. MEA
  • 8.9.1. South Africa
    • 8.9.1.1. Key country dynamics
    • 8.9.1.2. Regulatory framework
    • 8.9.1.3. Competitive scenario
    • 8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.3. UAE
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.4. Kuwait
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
  • 9.2.1. Innovators
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2024
  • 9.3.4. McKesson Corporation
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Cerner Corporation
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Siemens Healthineers GmbH
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Veradigm LLC
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. athenahealth, Inc.
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiativess
  • 9.3.9. NextGen Healthcare Inc.
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Koninklijke Philips N.V. (Royal Philips)
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. IBM Corporation
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. Agfa-Gevaert Group
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Wolters Kluwer N.V.
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Product benchmarking
    • 9.3.13.4. Strategic initiatives
  • 9.3.14. Becton, Dickinson and Company
    • 9.3.14.1. Company overview
    • 9.3.14.2. Financial performance
    • 9.3.14.3. Product benchmarking
    • 9.3.14.4. Strategic initiatives
  • 9.3.15. Cabot Technology Solutions
    • 9.3.15.1. Company overview
    • 9.3.15.2. Financial performance
    • 9.3.15.3. Product benchmarking
    • 9.3.15.4. Strategic initiatives
  • 9.3.16. GE HealthCare
    • 9.3.16.1. Company overview
    • 9.3.16.2. Financial performance
    • 9.3.16.3. Product benchmarking
    • 9.3.16.4. Strategic initiatives
  • 9.3.17. Nordic
    • 9.3.17.1. Company overview
    • 9.3.17.2. Financial performance
    • 9.3.17.3. Product benchmarking
    • 9.3.17.4. Strategic initiatives
  • 9.3.18. BeeKeeperAI
    • 9.3.18.1. Company overview
    • 9.3.18.2. Financial performance
    • 9.3.18.3. Product benchmarking
    • 9.3.18.4. Strategic initiatives
  • 9.3.19. BSCO Industries, Inc.
    • 9.3.19.1. Company overview
    • 9.3.19.2. Financial performance
    • 9.3.19.3. Product benchmarking
    • 9.3.19.4. Strategic initiatives